Frank Scheffler will be presenting at the EFMC-ISMC 2021 meeting on “Integration of Biocatalysis into Medicinal Chemistry Programs for Late-Stage Oxidised Derivatives using PolyCYPs Enzymes”. Check out his talk in session 24 on Biocatalysis and Late-stage functionalisation on Thursday 2nd September.

EFMC-ISMC 2021 will cover advances in drug discovery in major therapeutic areas, including bacterial and viral infections, diseases of the brain, heart, and respiratory system, fibrotic diseases and cancer. The meeting will also feature most recent advances in new technologies such as, artificial intelligence in drug discovery and chemical synthesis, the role carbohydrates in disease pathology and carbohydrate-based drug discovery, the exploitation of RNA as drug target, small molecule-induced stem cell differentiation, or the impact of cryo-EM on drug discovery and design. In a series of dedicated sessions, the interface between chemical biology and drug discovery will be highlighted, including topics such the use of chemical probes for target discovery, molecular imaging, and photochemical approaches. In response to frequent requests by attendees of previous conferences, two sessions will be dedicated to advances in synthetic methodology for drug discovery. Finally, particular emphasis will again be put on first time disclosures and recent highlights in medicinal chemistry.